[1] |
ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen.
Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
|
[2] |
PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng.
Progress of pharmacotherapy for heart failure
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381.
|
[3] |
LI Shaohua, YILI Hamujiang·KE Youmu, XU QI, SHAO Peipei, CHENG Lufeng.
Inhibitory effects of eplerenone on the mRNA and protein expression of Kv1.3 and other channels of CD4+T lymphocyte in patients with chronic heart failure
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1259-1264.
|
[4] |
TANG Hong-mei, TU Xing, CHAI Yu-na.
Experimental study on the rationality of amiloride off-label use in treating primary aldosteronism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1116-1120.
|
[5] |
YANG Yan-lang1,2, ZOU He-qun1, ZHANG Dao-you2, WANG Yu-wei2, LI Fan-xia2, GAO Chao-qing2, XU Hai-hong2, CHENG Xiao-mei2.
Renal tubular protection effect of combining benazepril and spironolactone in adriamycin-induced nephritic rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(4): 381-386.
|
[6] |
LIU Hua-qiang,YAN Mei-xing,WANG Shao-hua,SUN Xiao-lei.
Effects of bisoprolol with different drug administration time on the renin-angiotension-aldosterone system of non-dippers hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 101-104.
|
[7] |
HU Qun-li, LIANG Qun, CAI Qi-yun.
Effect of circadian variability of dipper blood pressure induced by valsartan in patients with non-dipper essential hypertension on levels of aldosterone
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(1): 116-118.
|
[8] |
LUO Bi-hui, ZENG Zhao-hua, WANG Xin-liang, HE Zhao-chu, SU Chen-jian.
Different role of aldosterone in cardiac hypertrophy and cardiac fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(12): 1397-1402.
|
[9] |
CHEN Xie-Xing, HONG Hua-Shan, CHEN Liang-Long, WANG Yi-Bo, YE Ming-Fang, JIANG Qiong.
Effects of spironolactone on cardiac function and serum brain natriuretic peptide levels in patients with chronic heart failure
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(4): 447-450.
|
[10] |
DUAN Xiao-Chun, WANG Jin-Ming, WANG Fang, LI Heng, QIN Jin-Mei.
Effects of valsartan and spironolactone on insulin-like growth factor-1 in cardiacmyocytes of spontaneously hypertensive rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(10): 1137-1141.
|
[11] |
HUli-Qun, CAI Qi-Yun, WANG Wei-Dong, lIU Jun.
Interference of valsartan on bloodPressure andPlasma angiotensinⅡ , aldosterone in salt sensitive essential hypertensivePatients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(4): 428-430.
|
[12] |
LI Xiao-Guang, CHEN Xue-Wen.
Low doses of digoxin, captopril, metoprolol and spironolactone in combination in treatment of elderly cardiac insufficiency
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(5): 463-464.
|